What to know before a third shot

Three or four shots a year is a caution, not a rule

You may hear three or four a year, often spaced three months apart. That is a rough warning, not a safe number proved for every joint.

By twelve to twenty-four months, people getting repeat cortisone did no better on average than people getting salt-water comparison shots. Researchers gave the salt water so they could compare pain and movement.

Some studies suggest repeat cortisone may speed cartilage loss. Other studies didn’t find that damage, so the long-term risk still isn’t settled.

Shorter relief is a reason to review the choice

If each round wears off sooner, don’t brush that off as bad luck. Tell the clinician how many good weeks you had and what you managed then.

Now comes the part worth slowing down for. Another shot makes more sense when you and the clinician agree on the task it should help.

At QC Kinetix, joint preservation means using non-surgical care to keep your own joint working and delay replacement. Its regenerative treatments may use your blood, spun and prepared at the clinic by a clinician.

The next visit should end with a clear follow-up

Before another round, choose one daily task that ought to get easier. Also agree on when you’ll check the soreness again.

Mention any plans for surgery on your knee or hip. Infection risk was higher when cortisone went into that joint during the three months before replacement.

A web page can’t settle this for your body. A good visit leaves you knowing why another round fits, or why it doesn’t.

Sources

1. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

2. A 2-year double-blind RCT of triamcinolone every 3 months versus saline found NO difference in joint space loss between groups and significantly improved pain and stiffness with repeated steroid injections, and the authors concluded that long-term intra-articular steroid injection is safe for the anatomical structure of the knee.

   Raynauld JP, et al. — Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.. Arthritis Rheum, 2003. DOI: 10.1002/art.10777.

3. A meta-analysis of 10 RCTs of RECURRENT intra-articular corticosteroid injections (2-8 injections per patient) found they often gave inferior or non-superior relief compared with hyaluronic acid, PRP, saline or orgotein at 3 months and beyond, and no benefit over placebo in pain or function at 12-24 months.

   Donovan RL, et al. — Effects of recurrent intra-articular corticosteroid injections for osteoarthritis at 3 months and beyond: a systematic review and meta-analysis in comparison to other injectables.. Osteoarthritis Cartilage, 2022. DOI: 10.1016/j.joca.2022.07.011.

4. In the Osteoarthritis Initiative cohort (684 propensity-matched participants), knees whose owners started intra-articular corticosteroids had radiographic OA worsening at 21.7 per 100 person-years versus 7.1 in comparators; the hazard ratio for Kellgren-Lawrence worsening was 3.02 for initiation, higher still for continuous use.

   Zeng C, et al. — Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative.. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.01.007.

5. In a 3,822-patient cohort, 31.3% of those who received corticosteroid injections went on to knee arthroplasty versus 5.0% of those who did not; after matching, the hazard ratio was 1.57 (95% CI 1.37 to 1.81) and each injection raised the absolute nine-year risk of arthroplasty by 9.4%.

   Wijn SRW, et al. — Intra-articular corticosteroid injections increase the risk of requiring knee arthroplasty.. Bone Joint J, 2020. DOI: 10.1302/0301-620X.102B5.BJJ-2019-1376.R1.

6. The RUbICOn mixed-methods HTA study, commissioned specifically to address uncertainty about recurrent injections, combined a UK primary-care cohort (2005-2020) linked to hospital data with a safety analysis, patient and clinician interviews, and a three-round Delphi to set research priorities - the current formal acknowledgement that the long-term risks and benefits of repeat injections remain unresolved.

   Whitehouse MR, et al. — RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study.. Health Technol Assess, 2025. DOI: 10.3310/LFAJ9337.

7. A meta-analysis of eight RCTs found the pooled effect of intra-articular corticosteroid on knee pain was -0.58 SMD (95% CI -0.88 to -0.27; NNT 5.1), with the effect approaching statistical insignificance at four months and a non-significant pooled risk ratio for adverse effects of 0.95.

   Saltychev M, et al. — The Magnitude and Duration of the Effect of Intra-articular Corticosteroid Injections on Pain Severity in Knee Osteoarthritis: A Systematic Review and Meta-Analysis.. Am J Phys Med Rehabil, 2020. DOI: 10.1097/PHM.0000000000001384.

8. The GRASP factorial randomized trial (708 patients with rotator cuff disorders) found subacromial corticosteroid injection provided NO long-term benefit over 12 months, and progressive exercise was not superior to a single best-practice advice session with a physiotherapist.

   Hopewell S, et al. — Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.. Lancet, 2021. DOI: 10.1016/S0140-6736(21)00846-1.